Psoriasis can support separate VA ratings for the skin and the joints, but the joint side of the disease is easy to miss.
We’ve reviewed files where the skin was rated under DC 7816 while documented psoriatic arthritis was never developed as a separate issue. The rating criteria were not what failed in those files. The joint disease was documented in the treatment record and never developed as a separate issue, which left compensable disability sitting in the file with no claim attached to it.
A psoriasis VA rating may include one evaluation for the skin condition and separate joint evaluations when psoriatic arthritis is present. The VA rates psoriasis under DC 7816 based on body coverage and systemic treatment, and the code directs the VA to evaluate complications such as psoriatic arthritis separately.
Active psoriatic arthritis involving two or more joints may be rated under DC 5002. Chronic joint residuals are evaluated through DC 5003 and the appropriate criteria for the affected joints. The VA assigns the higher evaluation rather than compensating the same joint symptoms under both methods.
Can Psoriasis and Psoriatic Arthritis Get Separate VA Ratings?
Yes. Psoriasis and psoriatic arthritis affect different parts of the body and may require separate evaluations.
DC 7816 covers the skin condition and specifically directs VA to rate complications such as psoriatic arthritis under the appropriate diagnostic code.
A veteran may have limited plaque coverage on exam day while joint swelling, stiffness, pain, or loss of motion creates a much greater level of disability. The joint condition should receive its own review rather than being treated as a footnote to the skin claim.
The VA evaluates psoriasis through the General Rating Formula for the Skin. The rating can depend on total body coverage, exposed area coverage, or the duration of systemic treatment required during the previous 12 months.
DC 7816 also directs the VA to consider distinct complications or clinical manifestations, including psoriatic arthritis, oral mucosal involvement, and nail manifestations, under the appropriate diagnostic code. A separate rating isn't automatic. The evidence still has to show what the additional condition is and how it should be evaluated.
Psoriatic arthritis doesn't always follow one rating path.
When two or more joints are involved as an active disease process, the VA may evaluate the condition under DC 5002. When the active disease leaves chronic joint residuals, the VA rates those residuals through DC 5003 and the criteria for the affected joints.
How Does VA Determine A Psoriasis VA Rating Under DC 7816?
A psoriasis VA disability rating under 7816 depends on two main tracks: skin coverage and systemic treatment.
You may qualify based on the percentage of the body or exposed areas affected, or based on the duration of qualifying systemic therapy. You do not have to meet both routes.
| Rating | What the File Has to Show | What It May Look Like |
|---|---|---|
| 0% | No more than topical treatment during the previous 12 months, with less than 5% of the total body or exposed areas affected and no higher criterion met. | Limited plaques managed with creams or ointments. The rating may not pay monthly compensation, but service connection can still matter if the condition worsens. |
| 10% | At least 5% but less than 20% of the total body or exposed areas, or intermittent systemic treatment required for less than 6 weeks during the previous 12 months. | Psoriasis affecting several limited areas, or a short course of qualifying systemic treatment. |
| 30% | 20% to 40% of the total body or exposed areas, or systemic treatment required for a total of 6 weeks or more but not constantly during the previous 12 months. | Broader skin involvement, or repeated treatment that adds up to at least 6 weeks. |
| 60% | More than 40% of the total body or exposed areas, or constant or near constant systemic treatment during the previous 12 months. | Extensive psoriasis or an ongoing systemic treatment plan documented across most of the year. |
The regulation also allows VA to evaluate the predominant disability under the criteria for disfigurement of the head, face, or neck or under the applicable scar criteria when those manifestations better describe the disability.
Do Biologics Like Humira Or Skyrizi Count As Systemic Treatment?
Yes. Injectable biologics generally qualify as systemic treatment because they are administered through the body rather than applied directly to the skin.
Medications such as Humira, Skyrizi, Tremfya, and Taltz may affect the rating when the record shows how long the treatment was required during the previous 12 months. The medication name alone is not enough. VA also needs the treatment schedule and duration.
Pharmacy and treatment records should show:
- Medication name
- Dosing schedule
- Start date
- End date, when applicable
- Whether treatment remained part of an ongoing plan
The number of injection dates alone may not show the full treatment period. A medication given every several weeks may still be part of continuous treatment across the year.
The General Rating Formula also includes phototherapy and photochemotherapy among the systemic treatments that may affect a psoriasis VA rating. The record should document the treatment dates, number of sessions, and overall duration.
- Biologic injections
- Oral medications such as methotrexate or cyclosporine
- Oral corticosteroids
- Oral retinoids
- Other immunosuppressive medications
- Phototherapy
- Photochemotherapy
- Corticosteroid creams or ointments
- Vitamin D analogues
- Topical retinoids
- Tar preparations
- Salicylic acid
- Topical calcineurin inhibitors
- Topical JAK medications
The VA measures exposed areas separately from total body coverage. Psoriasis concentrated on visible areas may support a compensable rating even when the overall body percentage is low.
How Does VA Determine A Psoriatic Arthritis Rating?
A psoriatic arthritis VA rating depends on whether VA evaluates the condition as an active multi joint disease or through chronic residuals in the affected joints.
DC 5002 applies to multi joint arthritis involving two or more joints as an active process. The criteria look at exacerbations, overall health impairment, and constitutional manifestations.
| Rating | What the File Has to Show | What the Record Should Explain |
|---|---|---|
| 20% | 1 or 2 incapacitating exacerbations per year with a confirmed diagnosis. | When the flares happened, which joints were affected, how long symptoms lasted, and what activity became difficult. |
| 40% | Symptom combinations productive of definite impairment of health objectively supported by examination findings, or incapacitating exacerbations occurring 3 or more times a year. | Repeated flares with documented effects on mobility, strength, daily activity, or overall health. |
| 60% | Weight loss and anemia productive of severe impairment of health, or severely incapacitating exacerbations occurring 4 or more times a year or a lesser number over prolonged periods. | Severe disease with prolonged or frequent episodes and clear effects beyond isolated joint pain. |
| 100% | Totally incapacitating active joint disease with constitutional manifestations. | Active systemic disease causing an exceptional level of overall impairment. |
These percentages apply to the active disease process. DC 5002 identifies psoriatic arthritis as one of the conditions that may be evaluated under this code.
What Does An Incapacitating Arthritis Flare Look Like In The Record?
The file should explain what made the flare incapacitating rather than using that word by itself.
Useful details may include:
- Which joints became painful, swollen, or difficult to move
- How long the flare lasted
- Whether walking, standing, gripping, lifting, dressing, or driving became difficult
- Whether normal activity had to stop or be sharply reduced
- Whether treatment, assistive devices, or time away from work was needed
The arthritis DBQ asks about the frequency and duration of incapacitating exacerbations, constitutional manifestations, weight loss, anemia, joint involvement, assistive devices, and occupational impact.
How Are Chronic Joint Residuals Rated?
When the active disease leaves ongoing joint problems, VA rates those chronic residuals under DC 5003 and the appropriate criteria for each affected joint.
That may include painful motion, limited range of motion, ankylosis, swelling, weakness, or other lasting impairment in the hands, wrists, knees, feet, spine, or other joints.
VA does not combine the active process rating with ratings for the same chronic residuals. It assigns the higher evaluation.
How Do You Get A VA Rating For Psoriasis Through Service Connection?
To get VA disability for psoriasis, the file needs to show how the condition connects to service.
That connection may be direct because psoriasis began during service. It may be based on aggravation because military service permanently worsened a preexisting condition. It may also be secondary when another service connected disability caused or aggravated the psoriasis.
For some veterans, PTSD may support a secondary claim when a medical opinion explains how the condition caused or aggravated psoriasis in that individual record. A general statement that stress can affect skin symptoms is not enough by itself.
Psoriatic arthritis follows a different path. DC 7816 expressly recognizes it as a potential complication of psoriasis and directs VA to evaluate it separately. The file still needs a competent diagnosis showing that the joint condition is psoriatic arthritis and evidence documenting its severity.
What Evidence Helps Support A Psoriasis VA Rating?
A strong psoriasis claim should document both the skin disease and any joint involvement.
One quiet skin exam or one normal joint appointment may not show what happens during a typical flare. The record should follow the condition across time.
Helpful evidence may include:
- Dermatology records showing plaque location, body coverage, exposed area involvement, and flare history
- Pharmacy records showing systemic medications, dosing schedules, and treatment duration
- Photos from active flares
- Rheumatology records identifying psoriatic arthritis and the joints involved
- Records describing swelling, painful motion, reduced range of motion, stiffness, weakness, or functional loss
- Treatment notes documenting the frequency and duration of arthritis exacerbations
- A skin or arthritis DBQ addressing the applicable rating criteria
- A VA nexus letter when the service connection pathway requires a medical opinion
The Skin Diseases DBQ records treatment duration during the previous 12 months and separately measures total body and exposed area involvement. The arthritis DBQ documents active disease, joint involvement, incapacitating exacerbations, systemic effects, assistive devices, and work impact.
A C&P exam may be important, but the examiner should not be the only person seeing the worst flare. Photos, treatment records, and pharmacy history can help show what one appointment may miss.
What Other Conditions Or Manifestations Can Matter In A Psoriasis Claim?
A psoriasis file should not stop at plaques and body coverage.
The condition may also affect the joints, nails, sleep, mental health, or other areas of daily function. Some problems may support secondary conditions, while others may be evaluated as distinct manifestations under the rating schedule.
Visible, painful, or persistent psoriasis can affect confidence, relationships, sleep, and daily life.
If medical evidence shows that service connected psoriasis caused or aggravated depression or anxiety, the diagnosed mental health condition may support secondary service connection.
The evidence still has to establish the relationship. The fact that both conditions exist isn't enough.
Itching, pain, and joint symptoms can interrupt sleep and affect daytime function.
Sleep problems don't automatically receive a separate rating. The record should clarify whether the sleep impairment is a symptom already considered elsewhere or a distinct diagnosed condition with separate functional effects.
Psoriasis affecting the head, face, or neck may be evaluated under the disfigurement criteria when disfigurement is the predominant disability. Scarring may also be evaluated under the applicable scar criteria.
A separate rating isn't automatic. The file has to show a distinct manifestation that isn't already compensated under the psoriasis evaluation.
DC 7816 specifically identifies nail manifestations as a type of clinical manifestation that may be evaluated separately under an appropriate diagnostic code.
Nail changes don't automatically create another rating. The record should identify the diagnosis, the functional effect, and the rating criteria that apply.
Can Separate Psoriasis Ratings Lead To An SMC-S Review?
Potentially, but the rating structure has to meet specific requirements.
One path to statutory SMC-S requires a single service connected disability rated at 100% and additional service connected disabilities independently rated at 60% or more. The additional disabilities must be separate and distinct from the 100% disability and involve different anatomical segments or bodily systems.
When psoriasis, psoriatic arthritis, and other conditions create a high combined rating, the file may warrant an SMC-S review under the statutory housebound rule. Whether the ratings satisfy the separate and distinct requirement depends on how VA has evaluated and characterized the disabilities.
How VetClaims Reviews Psoriasis Files
A psoriasis VA rating review should not stop at the skin condition alone.
VetClaims checks whether the file supports a separate psoriatic arthritis rating, whether systemic treatment such as biologic injections was counted correctly, and whether the evidence matches the rating level supported by the regulation.
The joint claim was never developed. The treatment history was documented but never translated into the correct rating. The C&P exam captured a quiet skin day but did not reflect the treatment record. The arthritis diagnosis was present, but no one documented the flares or lasting joint limitations.
VetClaims.ai is veteran founded, is not affiliated with the U.S. Department of Veterans Affairs or any government agency, and charges a flat one time fee with no percentage of back pay.
FAQs on VA Disability for Psoriasis
Can I Receive Separate VA Ratings For Both Psoriasis And Psoriatic Arthritis?
Yes. DC 7816 directs VA to rate complications like psoriatic arthritis separately under the right diagnostic code. The skin condition rates under DC 7816, while psoriatic arthritis rates under DC 5002, so a veteran can receive both ratings when the evidence supports both.
How Does Psoriatic Arthritis Connect To My Psoriasis Service Connection?
DC 7816 already names psoriatic arthritis as a complication of psoriasis, which gives the claim a built-in regulatory connection once psoriasis is service-connected. The claim should still identify psoriatic arthritis as secondary to service-connected psoriasis under DC 5002 and include evidence of joint symptoms, flares, and functional limits.
If Psoriasis And Psoriatic Arthritis Are Rated Separately, Do They Combine For A Higher Total?
Yes. The skin evaluation under DC 7816 and the joint evaluation under DC 5002 are separate disabilities, so they combine under 38 CFR § 4.25 rather than being added. The rule against combining active-process and chronic-residual ratings applies within the joint evaluation itself, not between the skin and the joints.
Is There A Presumptive Service Connection For Psoriasis Based On Military Service?
Usually no. Psoriasis is not presumptive for most veterans, so the claim normally needs a direct, aggravation, or secondary service connection. PACT Act exposure or Gulf War illness evidence may matter in some cases, depending on the veteran’s service history and medical record.
Does My Psoriasis Rating Change If The Plaques Clear Up For A While?
Not automatically. VA looks at the prior 12 months, so a quiet exam day should not erase documented flares or systemic therapy. A reduction is more likely only when the record shows sustained improvement, minimal coverage, and topical-only treatment over the rating period.